Milken Institute59 min
California's Solutions to Health Care
Anna Gorman, Kimberly Evon, Yiwen Li, Josh Ofman, Hugh Waters, Claudia Williams, Kim Avon
Panel, Conference Presentation
Chronic Disease Economic Impact (California, 2016):
- Direct healthcare spending on chronic illnesses totaled $112 billion.
- Including indirect costs (productivity losses and premature mortality), the total economic burden reached $378.3 billion.
- This $378.3 billion figure represents 14.5% of California's GDP.
- Cardiovascular conditions represent the largest slice of chronic disease spending.
- Over 61% of California adults are overweight or obese, driving 36% of chronic disease treatment costs.
- Demographic projections indicate the population aged 65+ will grow from 14% in 2016 to 23% within 20 years, disproportionately increasing chronic disease burdens.
Home Care Workforce Crisis:
- The California Employment Development Department projects a need to add 200,000 home care jobs by 2024 (a 36% increase).
- If full care needs are met, the state could require up to 600,000 additional workers by 2030, with some estimates reaching 3.2 million.
- Current turnover in the home care workforce stands at 33%.
- Institutional care is 30% to 40% more expensive than home-based care, yet home care options remain understaffed.
- In 2015, the median hourly wage for home care workers was $10.05, with an annual median salary of $14,000.
- 40.7% of home care workers rely on public programs for their own health insurance, and most lack employer-paid retirement or Social Security access.
- A CMMI-funded training pilot involving 6,000 home care providers resulted in reduced hospital stays, ER visits, and overall costs.
Prescription Drug Pricing and Innovation:
- Biologic medicines are increasingly viewed as essential solutions to rising disease costs, despite their high price tags, rather than the primary problem.
- Amgen notes that medicines account for 14–17% of total US medical spending, a figure consistent for decades.
- Cardiovascular disease costs are projected to rise from $600 billion to $900 billion by 2030.
- Alzheimer's disease is expected to cost society over $1 trillion by 2050.
- Industry partners (e.g., Amgen) are implementing risk-sharing agreements where manufacturers refund costs if patients suffer heart attacks while on medication or if cholesterol targets are not met.
- Amgen opposes direct price controls, arguing they stifle R&D; 95% of human clinical trials fail, requiring high-risk investment engines to function.
- The panel supports transparency legislation (like California's drug price reporting bill) but advocates for market-based value solutions over regulation.
Precision Medicine and Data Infrastructure:
- Only 62% of Americans are familiar with the term "precision medicine," despite its potential to treat individuals based on genomics, lifestyle, and environment.
- Current cancer drug utilization shows inefficiency: only 25% of patients benefit from prescribed drugs, meaning 75% of cancer drug spending is wasted.
- Targeted testing can yield significant savings; for example, KRAS gene testing for colorectal cancer could save $600 million annually.
- A BRCA test for breast cancer patients could reduce unnecessary chemotherapy by over 30%.
- The Obama administration's Precision Medicine Initiative aimed to aggregate data from one million Americans on an open platform to accelerate discovery.
- Current payment systems lag behind scientific capability, operating on "epidemiological averages" rather than individual patient needs (described as "Star Wars medicine in Flintstones healthcare").
- Only 25% of physicians feel confident making treatment decisions based on genomic data, and only 10% of doctors currently recommend such testing to patients.
- Manifest Med-X is creating health information exchanges in California to break down data silos between 60+ hospitals and payers, fostering pre-competitive collaboration.
Workforce and Community Health Models:
- Community health workers saved an estimated 165,000 lives in the US in 2015, with an economic value of up to $500 billion.
- Community health workers bridge gaps in cultural, linguistic, and physical access to care, particularly for populations with limited English proficiency.
- Barriers to scaling include antiquated payment models focused on volume rather than value.
- MACRA legislation is driving physician payment models toward quality measurement and alternative payment models (APMs).
- California faces specific challenges in closing care gaps due to its linguistic diversity, with some patients waiting six months for appointments due to a lack of linguistically competent providers.
Future Outlook and Strategic Priorities:
- Panelists agreed the transition from "break-fix" (volume-based) to "predict-prevent-protect" (value-based) models is critical.
- A robust federal budget and Medicaid expansion are seen as prerequisites for universal healthcare access.
- Key obstacles to progress include perverse financial incentives, political fragmentation, and a legal system that encourages defensive medicine.
- Empowering patient voices is identified as a necessary step to override discrete industry interests and drive holistic system change.
- There is a consensus that California must lead the nation by establishing a common information backbone and ambitious payment strategies that support home and community care.